Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PAMELA D MOORE

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1598838435
CMS profile
118001
Location
PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,374.14

113 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,356.56 111
Education $17.58 2

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 3; records 1–50 of 113 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PAMELA D MOORE

NPI 1598838435 · CMS profile ID 118001

Allopathic & Osteopathic Physicians / Internal Medicine

PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 3; records 1–50 of 113 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1598838435?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PAMELA D MOORE, NPI 1598838435, CMS profile ID 118001. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 113 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598838435?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). PAMELA D MOORE, NPI 1598838435, CMS profile ID 118001. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 113 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598838435?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
PAMELA D MOORE, NPI 1598838435, CMS profile ID 118001, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 3; records 1–50 of 113 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1598838435?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

113 matching records · $1,374.14 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 113 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 113.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $13.4712/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685678017 CMS
Allergan Inc. $13.0812/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670838953 CMS
Novo Nordisk Inc $7.1812/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682814557 CMS
Amarin Pharma Inc. $15.9512/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699268123 CMS
AstraZeneca Pharmaceuticals LP $13.7912/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685714975 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.5612/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684844947 CMS
Novo Nordisk Inc $7.5711/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 690109621 CMS
AbbVie, Inc. $16.9111/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648254279 CMS
Novo Nordisk Inc $12.5111/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674716921 CMS
Merck Sharp & Dohme Corporation $15.6411/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695870503 CMS
Novo Nordisk Inc $4.6111/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682814563 CMS
Novo Nordisk Inc $4.6111/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682814569 CMS
AstraZeneca Pharmaceuticals LP $14.1011/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685326085 CMS
Novo Nordisk Inc $2.0711/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682814573 CMS
Amarin Pharma Inc. $19.9310/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699245645 CMS
Allergan Inc. $12.3810/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670838949 CMS
Astellas Pharma US Inc $17.3210/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655698593 CMS
Amarin Pharma Inc. $6.0210/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699242533 CMS
Merck Sharp & Dohme Corporation $13.0710/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695779973 CMS
Novo Nordisk Inc $1.8410/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682814555 CMS
Allergan Inc. $11.4610/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670838945 CMS
Novo Nordisk Inc $15.1010/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674992621 CMS
Novo Nordisk Inc $16.2310/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674992617 CMS
Amarin Pharma Inc. $4.6110/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699228311 CMS
Novo Nordisk Inc $4.6509/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682814531 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $13.7409/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700387501 CMS
GlaxoSmithKline, LLC. $20.3609/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670384515 CMS
Novo Nordisk Inc $13.9209/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674551063 CMS
Novo Nordisk Inc $13.7809/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 690109567 CMS
Amarin Pharma Inc. $16.7909/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699217119 CMS
IBSA Pharma Inc. $15.0809/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682232443 CMS
AbbVie, Inc. $20.0809/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648254277 CMS
Amarin Pharma Inc. $6.5009/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699214399 CMS
Novo Nordisk Inc $17.4009/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674551057 CMS
Merck Sharp & Dohme Corporation $15.7409/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695724345 CMS
Novo Nordisk Inc $5.0708/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682814535 CMS
Amarin Pharma Inc. $4.3508/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699200417 CMS
Coloplast Corp $21.6208/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 696972639 CMS
Kowa Pharmaceuticals America, Inc. $21.0808/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 630287821 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $19.5108/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684844945 CMS
GlaxoSmithKline, LLC. $17.7608/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670944899 CMS
Merck Sharp & Dohme Corporation $17.2808/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695689157 CMS
Novo Nordisk Inc $20.9708/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674589801 CMS
Amarin Pharma Inc. $16.1408/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699194063 CMS
AstraZeneca Pharmaceuticals LP $15.2908/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685108969 CMS
Novo Nordisk Inc $3.3308/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682814549 CMS
Astellas Pharma US Inc $19.3408/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655698589 CMS
Novo Nordisk Inc $4.1008/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682814543 CMS
Amarin Pharma Inc. $4.5907/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699190095 CMS
GlaxoSmithKline, LLC. $16.6807/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670745621 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,374.14 113
PY2020 $293.54 19
PY2021 $266.59 11
PY2023 $38.13 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $150.00 1
PY2023 Principal investigator $81,329.92 42
PY2022 Principal investigator $230,331.53 69
PY2021 Principal investigator $235,861.88 64
PY2020 Principal investigator $331,535.42 56
PY2019 Principal investigator $588,251.30 60

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

69 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $2,325.82 12/23/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 965504777
Principal investigator 1 ABBVIE INC. $2,603.80 12/08/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890369701
Principal investigator 1 GlaxoSmithKline, LLC. $371.25 12/03/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 965504775
Principal investigator 1 GlaxoSmithKline, LLC. $5,148.40 12/02/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 943960025
Principal investigator 1 SANOFI US SERVICES INC. $3,010.12 11/28/2022 Non-covered Recipient Entity
Clinrx Research Joseph Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 935589191
Principal investigator 1 GlaxoSmithKline, LLC. $5,461.97 11/25/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 943960027
Principal investigator 1 GlaxoSmithKline, LLC. $2,544.75 11/23/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943960031
Principal investigator 1 ABBVIE INC. $1,376.75 11/09/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889819469
Principal investigator 1 GlaxoSmithKline, LLC. $325.00 11/09/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943960037
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 11/09/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943960057
Principal investigator 1 SANOFI US SERVICES INC. $750.00 11/07/2022 Non-covered Recipient Entity
Clinrx Research Joseph Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 935589214
Principal investigator 1 SANOFI US SERVICES INC. $3,010.12 11/02/2022 Non-covered Recipient Entity
Clinrx Research Joseph Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 935589203
Principal investigator 1 GlaxoSmithKline, LLC. $913.50 10/26/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 943960017
Principal investigator 1 ABBVIE INC. $101.69 10/14/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889816549
Principal investigator 1 ABBVIE INC. $37.42 10/13/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889815627
Principal investigator 1 ABBVIE INC. $6,931.45 10/13/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890368031
Principal investigator 1 ABBVIE INC. $9,546.95 10/12/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889814593
Principal investigator 1 ABBVIE INC. $240.00 09/30/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890366337
Principal investigator 1 ABBVIE INC. $150.00 09/29/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890366339
Principal investigator 1 ABBVIE INC. $12,830.15 09/08/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889809917
Principal investigator 1 ABBVIE INC. $5,429.70 09/07/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890366173
Principal investigator 1 GlaxoSmithKline, LLC. $2,012.25 09/06/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 943960021
Principal investigator 1 GlaxoSmithKline, LLC. $1,049.40 09/01/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943960051
Principal investigator 1 ABBVIE INC. $3,244.05 08/30/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890366335
Principal investigator 1 ABBVIE INC. $67.95 08/30/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890366535
Principal investigator 1 ABBVIE INC. $823.50 08/25/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890366389
Principal investigator 1 ABBVIE INC. $947.70 08/25/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890366393
Principal investigator 1 ABBVIE INC. $3,385.80 08/25/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890366395
Principal investigator 1 ABBVIE INC. $2,917.35 08/25/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890366397
Principal investigator 1 GlaxoSmithKline, LLC. $10,923.94 08/24/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 943960023
Principal investigator 1 ABBVIE INC. $150.71 08/19/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889807217
Principal investigator 1 GlaxoSmithKline, LLC. $1,049.40 08/17/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943960043
Principal investigator 1 ABBVIE INC. $1,839.70 08/11/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890366341
Principal investigator 1 ABBVIE INC. $21,023.25 08/10/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889804433
Principal investigator 1 ABBVIE INC. $76.82 08/03/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890366387
Principal investigator 1 SANOFI US SERVICES INC. $1,356.47 08/02/2022 Non-covered Recipient Entity
Clinrx Research Joseph Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 935589235
Principal investigator 1 ABBVIE INC. $150.00 07/25/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890364825
Principal investigator 1 ABBVIE INC. $240.00 07/20/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890364821
Principal investigator 1 GlaxoSmithKline, LLC. $361.35 07/20/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943960049
Principal investigator 1 GlaxoSmithKline, LLC. $391.50 07/16/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 943960015
Principal investigator 1 ABBVIE INC. $9,238.95 07/07/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889798721
Principal investigator 1 ABBVIE INC. $2,134.95 07/05/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890364823
Principal investigator 1 ABBVIE INC. $525.00 06/28/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890364005
Principal investigator 1 ABBVIE INC. $3,894.10 06/23/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890364009
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 06/15/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943960047
Principal investigator 1 GlaxoSmithKline, LLC. $55.78 06/14/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 943960019
Principal investigator 1 ABBVIE INC. $256.50 06/08/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889794255
Principal investigator 1 GlaxoSmithKline, LLC. $361.35 06/08/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943960053
Principal investigator 1 GlaxoSmithKline, LLC. $361.35 06/01/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943960039
Principal investigator 1 GlaxoSmithKline, LLC. $1,844.37 05/11/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943960033
Principal investigator 1 ABBVIE INC. $5,680.95 05/05/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889790097
Principal investigator 1 ABBVIE INC. $98.59 04/25/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890362889
Principal investigator 1 GlaxoSmithKline, LLC. $4,170.87 04/21/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943960035
Principal investigator 1 ABBVIE INC. $320.00 04/14/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890362885
Principal investigator 1 ABBVIE INC. $200.00 04/14/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890362887
Principal investigator 1 ABBVIE INC. $245.89 04/13/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889785355
Principal investigator 1 ABBVIE INC. $3,652.10 04/07/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889783811
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 04/06/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943960029
Principal investigator 1 ABBVIE INC. $8,362.80 03/17/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiolx2FNorethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 890361459
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 03/16/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943960041
Principal investigator 1 GlaxoSmithKline, LLC. $325.00 03/16/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943960045
Principal investigator 1 GlaxoSmithKline, LLC. $6,000.00 03/16/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943960055
Principal investigator 1 GlaxoSmithKline, LLC. $22,987.80 03/16/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 943960059
Principal investigator 1 ABBVIE INC. $9,804.00 03/08/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889779613
Principal investigator 1 ABBVIE INC. $2,697.85 02/16/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 889777459
Principal investigator 1 ABBVIE INC. $3,967.90 02/03/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (TRAVERSE) No dispute reported 06/30/2026 889775563
Principal investigator 1 ABBVIE INC. $3,397.90 01/13/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 889773889
Principal investigator 1 ABBVIE INC. $147.50 01/06/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 889772253
Principal investigator 1 ABBVIE INC. $18,180.05 01/06/2022 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (TRAVERSE) No dispute reported 06/30/2026 889772255